Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03196947
What this trial is testing

Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Allarity Therapeutics 1
Early research (Phase 1)Looking for participantsNCT05759793
What this trial is testing

CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia
Nanjing IASO Biotechnology Co., Ltd. 12
Early research (Phase 1)Not Yet RecruitingNCT06655519
What this trial is testing

An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia
Peking University People's Hospital 12
Testing effectiveness (Phase 2)Looking for participantsNCT04271644
What this trial is testing

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Who this might be right for
Multiple MyelomaNeoplasm, Plasma CellMultiple Myeloma in Relapse
Chongqing Precision Biotech Co., Ltd 80
Testing effectiveness (Phase 2)Temporarily pausedNCT06232044
What this trial is testing

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Alliance for Clinical Trials in Oncology 88
Very early researchLooking for participantsNCT06732232
What this trial is testing

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

Who this might be right for
RelapsedRefractoryMultiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd 12
Testing effectiveness (Phase 2)UnknownNCT01541332
What this trial is testing

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Oncotherapeutics 70
Testing effectiveness (Phase 2)Ended earlyNCT02075021
What this trial is testing

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
NYU Langone Health 3
Testing effectiveness (Phase 2)Study completedNCT00134004
What this trial is testing

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 210
Testing effectiveness (Phase 2)Ended earlyNCT00005852
What this trial is testing

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+3 more
H. Lee Moffitt Cancer Center and Research Institute
Not applicableStudy completedNCT02608515
What this trial is testing

A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Genesis Pharma S.A. 207
Large-scale testing (Phase 3)Ended earlyNCT04549363
What this trial is testing

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 16
Early research (Phase 1)Study completedNCT00025415
What this trial is testing

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Undifferentiated LeukemiaAIDS-related Peripheral/Systemic Lymphoma+78 more
National Cancer Institute (NCI) 60
Early research (Phase 1)Study completedNCT00091624
What this trial is testing

Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Celgene Corporation 77
Large-scale testing (Phase 3)UnknownNCT00003603
What this trial is testing

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Riverside Haematology Group 660
Post-approval studies (Phase 4)Study completedNCT05555329
What this trial is testing

Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study

Who this might be right for
Multiple Myeloma in RelapseMultiple MyelomaMultiple Myeloma, Refractory
Amsterdam UMC, location VUmc 12
Testing effectiveness (Phase 2)Looking for participantsNCT06920251
What this trial is testing

Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Seoul National University Hospital 40
Early research (Phase 1)Ended earlyNCT04570631
What this trial is testing

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 4
Early research (Phase 1)Study completedNCT02426723
What this trial is testing

Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients

Who this might be right for
Multiple Myeloma
JW Pharmaceutical 25
Testing effectiveness (Phase 2)Ended earlyNCT01078441
What this trial is testing

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

Who this might be right for
Refractory Multiple Myeloma
National Cancer Institute (NCI) 2
Next Page